Venous thromboembolism: What pharmacists know? What do they need?

J Oncol Pharm Pract. 2016 Feb;22(1):135-41. doi: 10.1177/1078155214560639. Epub 2014 Nov 25.

Abstract

Introduction: Venous thromboembolism is common in cancer. Low-molecular weight heparins are recommended for prolonged treatment (3-6 months or more if the cancer is active) and prevention of recurrence of venous thromboembolism in cancer. Community pharmacists are often faced with questions from patients. The main objective of this study was to describe the organization, practices and knowledge of pharmacists in care of venous thromboembolism in cancer patients.

Methods: A descriptive survey was conducted electronically in October and November 2013 with pharmacists in the Champagne-Ardenne region. The questionnaire collected data on the general organization of the pharmacy, management of outpatients with cancer and thrombosis, and the level of knowledge regarding recommendations on the management of thrombosis in patients with cancer.

Results: The participation rate was 31.6%. In 93% of cases, pharmacists had no particular expertise in oncology and/or supportive care. In addition, 96% did not know the existence of recommendations for "thrombosis in cancer." Finally, 49% gave the correct answer to the case report (low-molecular weight heparins).

Conclusion: Training sessions on the management of venous thromboembolism in cancer are currently available to pharmacists in the region. A new assessment of knowledge will be performed at the end of the year 2014. This regional experience is now extended to a national level (all French regions).

Keywords: Pharmacists; cancer; recommendations; thrombosis.

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / therapeutic use*
  • Female
  • Health Knowledge, Attitudes, Practice
  • Heparin, Low-Molecular-Weight / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications
  • Pharmacists
  • Recurrence
  • Surveys and Questionnaires
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology

Substances

  • Anticoagulants
  • Heparin, Low-Molecular-Weight